GO:0070857 regulation of bile acid biosynthetic process: Metabolic Control Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070857 describes any process that modulates the frequency, rate or extent of bile acid biosynthesis, a core liver metabolic pathway.
• Bile acid synthesis is controlled by a negative feedback loop in which farnesoid X receptor (FXR, NR1H4) activation in the intestine and liver suppresses CYP7A1, the rate-limiting enzyme.
• Gut microbiota reshape the bile acid pool by deconjugation, dehydroxylation and epimerization, generating secondary bile acids that act as signaling molecules.
• Dysregulated bile acid biosynthesis contributes to cholestatic liver disease, nonalcoholic fatty liver disease, obesity, type 2 diabetes and dyslipidemia.
• Key regulatory nodes include CYP7A1, CYP8B1, CYP27A1, FXR (NR1H4), FGF19, FGFR4, SHP (NR0B2) and the ileal bile acid transporter ASBT (SLC10A2).
• CRISPR knockout, point-mutation, knock-in and overexpression models enable causal testing of these regulatory nodes in hepatocytes and animal models.
Description
Bile acids are amphipathic steroid molecules synthesized from cholesterol in the liver, where they facilitate lipid absorption and also function as hormone-like signaling molecules that regulate glucose, lipid and energy metabolism. The Gene Ontology term GO:0070857, regulation of bile acid biosynthetic process, captures the diverse cellular and systemic inputs that set the rate of bile acid production. Because bile acid synthesis is tightly coupled to whole-body metabolic and immunological homeostasis, its dysregulation is implicated in cholestasis, fatty liver disease, obesity, type 2 diabetes and dyslipidemia. Understanding how this process is regulated therefore has direct translational relevance for metabolic and hepatobiliary disease research. This article integrates the QuickGO definition with verified PubMed literature to outline the mechanisms, key genes, disease links and experimental models used to study GO:0070857.
regulation of bile acid biosynthetic process At A Glance
| GO ID | GO:0070857 |
|---|---|
| GO term | regulation of bile acid biosynthetic process |
| Ontology | biological_process |
| Synonym | regulation of bile acid anabolism; regulation of bile acid biosynthesis; regulation of bile acid formation; regulation of bile acid synthesis |
| Major function | Modulates the rate of bile acid biosynthesis from cholesterol in the liver |
| Key regulators | FXR (NR1H4), SHP (NR0B2), FGF19, FGFR4, CYP7A1, CYP8B1 |
| Tissue context | Primarily liver and intestine, with systemic metabolic feedback |
| Microbiota link | Gut bacteria deconjugate and dehydroxylate bile acids, altering feedback on synthesis |
What Is GO:0070857?
GO:0070857, regulation of bile acid biosynthetic process, is defined as any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of bile acids. In practice, this includes transcriptional control of bile acid biosynthetic enzymes, feedback signaling by nuclear receptors and fibroblast growth factors, and microbiota-dependent modification of the bile acid pool that feeds back on synthesis.
Why Is regulation of bile acid biosynthetic process Important in Cell Biology?
Regulation of bile acid biosynthesis is important because bile acids are not only detergents for dietary lipid absorption but also potent signaling molecules that control glucose and lipid metabolism, inflammation and energy expenditure. The pathway is a validated drug target: FXR agonists and FGF19 analogues are under investigation for cholestatic and metabolic liver diseases. Consequently, researchers studying GO:0070857 need robust genetic models to dissect causal relationships between regulatory nodes and disease phenotypes.
• Controls cholesterol catabolism and whole-body cholesterol balance.
• Regulates dietary lipid absorption and fat-soluble vitamin uptake.
• Acts as a signaling hub for glucose and lipid homeostasis via FXR and TGR5.
• Modulates inflammation and immune homeostasis in liver and intestine.
• Shapes gut microbiota composition and is reciprocally modified by it.
• Dysregulation is linked to cholestasis, NAFLD, obesity and type 2 diabetes.
• Provides pharmacological targets such as FXR and FGF19 for metabolic disease.
• Serves as a paradigm for nuclear receptor feedback control of metabolism.
What Happens During regulation of bile acid biosynthetic process?
Cholesterol conversion and the classic pathway
In simple terms: The liver turns cholesterol into bile acids through a series of enzymatic steps.
Bile acid biosynthesis begins with cholesterol and proceeds through the classic (neutral) pathway initiated by CYP7A1, the rate-limiting enzyme, and the alternative (acidic) pathway initiated by CYP27A1. CYP8B1 controls the ratio of cholic acid to chenodeoxycholic acid, influencing pool hydrophobicity and signaling properties. Regulation of this process sets the overall flux from cholesterol to bile acids.
FXR-SHP negative feedback in the liver
In simple terms: When bile acids build up, a sensor in the liver turns down their production.
Farnesoid X receptor (FXR, NR1H4) is activated by bile acids and induces small heterodimer partner (SHP, NR0B2), which represses CYP7A1 transcription, forming a negative feedback loop. This feedback prevents bile acid accumulation and cholestatic injury. FXR also regulates other genes controlling bile acid transport and conjugation.
Intestinal FXR-FGF19 signaling
In simple terms: The gut senses bile acids and sends a hormone signal to the liver to slow bile acid production.
In ileal enterocytes, FXR activation induces FGF19 (FGF15 in mice), which travels to the liver and activates FGFR4/β-Klotho to suppress CYP7A1. This gut-liver axis integrates nutrient and bile acid signals to fine-tune synthesis. Disruption of this axis alters bile acid pool size and metabolic phenotypes.
Microbiota-dependent modification of the bile acid pool
In simple terms: Gut bacteria chemically modify bile acids, changing the signals that control synthesis.
Gut microbiota deconjugate, dehydroxylate and epimerize bile acids, producing secondary bile acids such as deoxycholic acid and lithocholic acid. These metabolites have distinct FXR and TGR5 activities and thus modulate feedback regulation of biosynthesis. Dietary lipids influence microbiota composition and consequently bile acid signaling.
Hormonal and metabolic inputs
In simple terms: Insulin, glucagon and other metabolic signals also adjust bile acid production.
Bile acid synthesis is influenced by hormonal and nutritional status, including insulin and glucagon signaling, and by circadian rhythms. These inputs allow bile acid production to match metabolic demand and nutrient availability. Integration of these signals with FXR-FGF19 feedback maintains systemic metabolic homeostasis.
Key Genes Involved in GO:0070857 regulation of bile acid biosynthetic process
The following genes and proteins are central to the regulation of bile acid biosynthesis and are frequently studied in metabolic and hepatobiliary research.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CYP7A1 | Rate-limiting enzyme of classic bile acid synthesis | Target of FXR-SHP and FGF19 feedback; knockout models show altered bile acid pool |
| CYP8B1 | 12α-hydroxylase controlling cholic acid synthesis | Determines bile acid composition and hydrophobicity |
| CYP27A1 | Sterol 27-hydroxylase initiating alternative pathway | Linked to cerebrotendinous xanthomatosis and macrophage cholesterol metabolism |
| NR1H4 (FXR) | Bile acid-activated nuclear receptor | Master regulator of bile acid, lipid and glucose homeostasis |
| NR0B2 (SHP) | Orphan nuclear receptor mediating FXR feedback | Represses CYP7A1 transcription |
| FGF19 | Intestinal hormone suppressing CYP7A1 | Gut-liver feedback signal; therapeutic candidate |
| FGFR4 | Hepatic receptor for FGF19 | Mediates FGF19 suppression of bile acid synthesis |
| KLB (β-Klotho) | Co-receptor for FGF19-FGFR4 signaling | Required for FGF19 activity in liver |
| SLC10A2 (ASBT) | Ileal apical bile acid transporter | Controls intestinal bile acid reabsorption and FXR signaling |
| ABCB11 (BSEP) | Canalicular bile acid export pump | Mutations cause progressive familial intrahepatic cholestasis |
| ABCC2 (MRP2) | Canalicular organic anion transporter | Bile acid and bilirubin export; cholestasis relevance |
| SLCO1B1/1B3 | Hepatic sinusoidal bile acid uptake transporters | Regulate hepatic bile acid exposure |
| TGR5 (GPBAR1) | Membrane bile acid receptor | Mediates metabolic and inflammatory effects of bile acids |
| VDR | Vitamin D receptor activated by secondary bile acids | Links bile acids to intestinal homeostasis |
| PXR (NR1I2) | Xenobiotic receptor regulating bile acid detoxification | Modulates bile acid metabolism under cholestasis |
| CAR (NR1I3) | Constitutive androstane receptor | Regulates bile acid detoxification enzymes |
| SLC27A5 (BACS) | Bile acid-CoA synthetase for conjugation | Required for bile acid amidation |
| BAAT | Bile acid-CoA:amino acid N-acyltransferase | Conjugates bile acids with glycine or taurine |
How Is regulation of bile acid biosynthetic process Regulated?
Regulation of bile acid biosynthesis is dominated by a negative feedback loop in which bile acids activate FXR, inducing SHP in the liver and FGF19 in the intestine; SHP and FGF19-FGFR4 signaling then repress CYP7A1 transcription. This loop is modulated by the gut microbiota, which converts primary bile acids into secondary species with altered receptor activity. Additional layers include circadian control, hormonal signals such as insulin and glucagon, and nuclear receptors such as PXR and CAR that detoxify bile acids under cholestatic stress. Dietary lipid intake influences microbiota composition and bile acid signaling, further tuning the pathway.
regulation of bile acid biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CYP7A1 | Altered bile acid pool and cholesterol metabolism | Liver-specific knockout or overexpression in mice |
| NR1H4 (FXR) | Cholestasis, NAFLD, metabolic syndrome | FXR knockout and knock-in reporter models |
| FGF19 | Cholestatic and metabolic liver disease | Transgenic overexpression or knockout of FGF15 in mice |
| ABCB11 (BSEP) | Progressive familial intrahepatic cholestasis | Patient-derived mutations in knock-in models |
| SLC10A2 (ASBT) | Bile acid malabsorption and diarrhea | Intestinal-specific knockout models |
Cholestatic liver disease and bile acid overload
When bile acid biosynthesis and export are dysregulated, bile acids accumulate in the liver, causing cholestatic injury and fibrosis. Mutations in canalicular transporters such as ABCB11 cause progressive familial intrahepatic cholestasis, illustrating the importance of coordinated regulation of synthesis and transport. FXR agonists are being developed to suppress bile acid synthesis and promote detoxification in cholestasis.
NAFLD, obesity and type 2 diabetes
Altered bile acid signaling contributes to nonalcoholic fatty liver disease, obesity, type 2 diabetes and dyslipidemia by affecting FXR and TGR5-dependent metabolic pathways. Bile acid pool composition and size are associated with insulin resistance and hepatic steatosis in human and animal studies. Targeting the FXR-FGF19 axis is therefore a strategy for metabolic disease.
Gut microbiota, inflammation and immune homeostasis
Microbiota-dependent bile acid modifications influence intestinal inflammation and immune cell function, linking GO:0070857 to inflammatory bowel disease and metabolic inflammation. Secondary bile acids activate receptors such as VDR and TGR5, shaping mucosal immunity. Dietary lipids can shift this balance, with consequences for metabolic and inflammatory phenotypes.
From regulation of bile acid biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CYP7A1 alter bile acid pool and metabolic phenotype? | CYP7A1 knockout (constitutive or liver-specific) |
| Does a patient FXR variant impair feedback repression? | FXR point-mutation knock-in |
| Can FGF19 rescue cholestatic injury? | FGF19 overexpression or transgenic knock-in |
| What is the role of ASBT in intestinal bile acid reabsorption? | SLC10A2 knockout or tagged knock-in |
| How does BSEP mutation affect bile acid export? | ABCB11 point-mutation knock-in |
| Which regulatory nodes control CYP7A1 transcription? | CRISPR knockout or reporter knock-in in hepatocyte cell lines |
How to Study the regulation of bile acid biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcript levels of bile acid genes | Assess CYP7A1, CYP8B1, FXR target expression |
| ChIP-seq | Transcription factor binding at promoters | Map FXR and SHP occupancy |
| LC-MS/MS bile acid profiling | Bile acid species and pool size | Quantify pathway flux in liver, serum, feces |
| 16S rRNA sequencing | Gut microbiota composition | Link microbiota to bile acid modification |
| CRISPR knockout | Loss-of-function phenotype | Test causal role of regulatory genes |
| CRISPR knock-in | Tagged or mutant protein expression | Study patient variants and localization |
| Overexpression | Gain-of-function effects | Test FGF19 or FXR rescue |
| Organoid culture | Human-relevant bile acid regulation | Validate findings in primary-like tissue |
Transcriptional and chromatin assays
RNA-seq and ChIP-seq can quantify expression of bile acid biosynthetic genes and map FXR, SHP and other transcription factor binding at promoters such as CYP7A1. Reporter assays using luciferase or CRISPR knock-in of fluorescent tags enable functional dissection of regulatory elements.
Bile acid profiling by mass spectrometry
LC-MS/MS quantification of bile acids in liver, serum, bile and feces provides a direct readout of pathway flux and pool composition. This method is essential for linking genetic perturbations to changes in bile acid species such as cholic acid and chenodeoxycholic acid.
Microbiota and gnotobiotic studies
16S rRNA sequencing and gnotobiotic or antibiotic-treated models reveal how gut bacteria modify bile acids and feed back on synthesis. Fecal microbiota transplantation and defined bacterial consortia can test causal roles of specific taxa.
Genetically engineered cell and animal models
CRISPR knockout, point-mutation knock-in and overexpression in hepatocyte cell lines and mouse models allow causal testing of regulatory genes. Primary human hepatocytes and organoids provide translational validation.
How CRISPR Can Be Used to Study GO:0070857 regulation of bile acid biosynthetic process
Knockout
CRISPR knockout of genes such as CYP7A1, NR1H4 or FGF19 in hepatocyte cell lines and mouse models can reveal their necessity in bile acid feedback regulation. Liver-specific knockout avoids developmental compensation and clarifies tissue-specific roles.
Point Mutation
Point-mutation knock-in of patient variants in FXR, ABCB11 or other genes allows precise testing of how single amino acid changes alter bile acid synthesis and transport. This approach links genotype to cholestatic or metabolic phenotypes.
Knock-in
Knock-in of fluorescent or epitope tags at endogenous loci enables tracking of CYP7A1, FXR or FGF19 expression and localization without overexpression artifacts. Reporter knock-in can monitor transcriptional responses to bile acid signals.
Overexpression
Overexpression of FGF19, SHP or constitutively active FXR can suppress CYP7A1 and protect against cholestatic injury in models. Overexpression models are useful for testing therapeutic rescue of bile acid overload.
How EDITGENE Supports regulation of bile acid biosynthetic process Research
Researchers studying regulation of bile acid biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in bile acid feedback, transport or metabolic disease. EDITGENE provides CRISPR-based cell and animal models to test these hypotheses with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for regulation of bile acid biosynthetic process research.
Frequently Asked Questions About regulation of bile acid biosynthetic process
What is GO:0070857 regulation of bile acid biosynthetic process?
It is a Gene Ontology biological process term describing any process that modulates the frequency, rate or extent of bile acid biosynthesis from cholesterol.
What genes are involved in regulation of bile acid biosynthetic process?
Key genes include CYP7A1, CYP8B1, CYP27A1, NR1H4 (FXR), NR0B2 (SHP), FGF19, FGFR4, SLC10A2 and ABCB11.
How does FXR regulate bile acid synthesis?
FXR is activated by bile acids and induces SHP in liver and FGF19 in intestine, which together repress CYP7A1 transcription.
What is the role of the gut microbiota in bile acid regulation?
Gut bacteria deconjugate and dehydroxylate bile acids, producing secondary bile acids that alter FXR and TGR5 signaling and feedback on synthesis.
Which diseases are linked to dysregulated bile acid biosynthesis?
Cholestatic liver disease, nonalcoholic fatty liver disease, obesity, type 2 diabetes and dyslipidemia are associated with altered bile acid regulation.
What experimental models are used to study bile acid biosynthesis regulation?
CRISPR knockout, point-mutation knock-in, overexpression cell lines and mouse models, combined with bile acid profiling and RNA-seq, are commonly used.
Why is CYP7A1 considered rate-limiting?
CYP7A1 catalyzes the first committed step of the classic bile acid synthesis pathway and is the main target of feedback regulation.
How do FGF19 and FGFR4 control bile acid synthesis?
Intestinal FGF19 activates hepatic FGFR4/β-Klotho to suppress CYP7A1, providing a gut-liver feedback mechanism.
Can CRISPR screens identify new regulators of bile acid biosynthesis?
Yes, genome-wide CRISPR screens can uncover novel genes modulating FXR activity and bile acid pathway flux.
What is the difference between primary and secondary bile acids?
Primary bile acids are synthesized in the liver, while secondary bile acids are produced by microbial modification in the gut.
Conclusion
GO:0070857, regulation of bile acid biosynthetic process, is a central metabolic control node that integrates nuclear receptor signaling, gut-liver feedback and microbiota-derived metabolites to set the rate of bile acid production. Its dysregulation is mechanistically linked to cholestatic, metabolic and inflammatory diseases, making it a high-value target for research and drug development. CRISPR-based knockout, knock-in, point-mutation and overexpression models, combined with bile acid profiling and multi-omics, provide the tools needed to dissect this pathway and translate findings into therapies.
References
- 1. Jia W et al.. 2024. Bile acid signaling in the regulation of whole body metabolic and immunological homeostasis.. Sci China Life Sci 67(5):865-878 PMID: 37515688
- 2. Chávez-Talavera O et al.. 2017. Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease.. Gastroenterology 152(7):1679-1694.e3 PMID: 28214524
- 3. Ramírez-Pérez O et al.. 2017. The Role of the Gut Microbiota in Bile Acid Metabolism.. Ann Hepatol 16(Suppl. 1: s3-105.):s15-s20 PMID: 29080339
- 4. Cai J et al.. 2022. Bile acid metabolism and signaling, the microbiota, and metabolic disease.. Pharmacol Ther 237:108238 PMID: 35792223
- 5. Chiang JY. 2013. Bile acid metabolism and signaling.. Compr Physiol 3(3):1191-212 PMID: 23897684
- 6. Schoeler M et al.. 2019. Dietary lipids, gut microbiota and lipid metabolism.. Rev Endocr Metab Disord 20(4):461-472 PMID: 31707624
- 7. Di Ciaula A et al.. 2017. Bile Acid Physiology.. Ann Hepatol 16(Suppl. 1: s3-105.):s4-s14 PMID: 29080336
- 8. Chiang JYL et al.. 2022. Discovery of farnesoid X receptor and its role in bile acid metabolism.. Mol Cell Endocrinol 548:111618 PMID: 35283218
